Metallothionein expression in canine and feline mammary and melanotic tumours

Z. Dincer, B. Jasani, S. Haywood, J. E. Mullins, I. C. Fuentealba

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Moderate to strong immunohistochemical metallothionein (MT) positivity (MT expression) is associated with a poor prognosis in some human tumours. The aim of this study was to determine MT expression in mammary tumours and cutaneous melanomas in dogs and cats. Canine (67) and feline (47) mammary tumours, and cutaneous melanomas (canine 40, feline 26) were immunolabelled with MT monoclonal antibody E9. The overall incidence of MT expression of these tumours was similar to that observed in various human neoplasms. However, a striking interspecies difference was detected. In dogs, MT expression occurred in 100% of benign and 57% of malignant mammary tumours. In cats, however, 30% of malignant mammary tumours expressed MT but benign mammary tumours and cases of fibroadenomatous hyperplasia did not. Moderate to strong MT immunoreactivity was detected in 30% of benign and 25% of malignant cutaneous melanomas in dogs, and in 6% of malignant melanomas in cats. The findings in feline mammary tumours resembled findings reported in human breast cancer, but the cause of tumour-associated MT expression is unknown. Studies are in progress to determine whether the MT state (apo [metal-free] or holo [metal-bound]) accounts for the paradoxical association of MT expression with individual types of tumours and the animal species in which they arise.

Original languageEnglish
Pages (from-to)130-136
Number of pages7
JournalJournal of Comparative Pathology
Volume125
Issue number2-3
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Metallothionein
metallothionein
Felidae
breasts
Canidae
cats
Breast Neoplasms
mammary neoplasms (animal)
neoplasms
dogs
melanoma
Melanoma
Cats
Dogs
Neoplasms
Metals
metals
Skin
hyperplasia
breast neoplasms

ASJC Scopus subject areas

  • Animal Science and Zoology

Cite this

Dincer, Z., Jasani, B., Haywood, S., Mullins, J. E., & Fuentealba, I. C. (2001). Metallothionein expression in canine and feline mammary and melanotic tumours. Journal of Comparative Pathology, 125(2-3), 130-136. https://doi.org/10.1053/jcpa.2001.0488

Metallothionein expression in canine and feline mammary and melanotic tumours. / Dincer, Z.; Jasani, B.; Haywood, S.; Mullins, J. E.; Fuentealba, I. C.

In: Journal of Comparative Pathology, Vol. 125, No. 2-3, 2001, p. 130-136.

Research output: Contribution to journalArticle

Dincer, Z, Jasani, B, Haywood, S, Mullins, JE & Fuentealba, IC 2001, 'Metallothionein expression in canine and feline mammary and melanotic tumours', Journal of Comparative Pathology, vol. 125, no. 2-3, pp. 130-136. https://doi.org/10.1053/jcpa.2001.0488
Dincer, Z. ; Jasani, B. ; Haywood, S. ; Mullins, J. E. ; Fuentealba, I. C. / Metallothionein expression in canine and feline mammary and melanotic tumours. In: Journal of Comparative Pathology. 2001 ; Vol. 125, No. 2-3. pp. 130-136.
@article{8802f679fc9f4893a62639ec4500aa21,
title = "Metallothionein expression in canine and feline mammary and melanotic tumours",
abstract = "Moderate to strong immunohistochemical metallothionein (MT) positivity (MT expression) is associated with a poor prognosis in some human tumours. The aim of this study was to determine MT expression in mammary tumours and cutaneous melanomas in dogs and cats. Canine (67) and feline (47) mammary tumours, and cutaneous melanomas (canine 40, feline 26) were immunolabelled with MT monoclonal antibody E9. The overall incidence of MT expression of these tumours was similar to that observed in various human neoplasms. However, a striking interspecies difference was detected. In dogs, MT expression occurred in 100{\%} of benign and 57{\%} of malignant mammary tumours. In cats, however, 30{\%} of malignant mammary tumours expressed MT but benign mammary tumours and cases of fibroadenomatous hyperplasia did not. Moderate to strong MT immunoreactivity was detected in 30{\%} of benign and 25{\%} of malignant cutaneous melanomas in dogs, and in 6{\%} of malignant melanomas in cats. The findings in feline mammary tumours resembled findings reported in human breast cancer, but the cause of tumour-associated MT expression is unknown. Studies are in progress to determine whether the MT state (apo [metal-free] or holo [metal-bound]) accounts for the paradoxical association of MT expression with individual types of tumours and the animal species in which they arise.",
author = "Z. Dincer and B. Jasani and S. Haywood and Mullins, {J. E.} and Fuentealba, {I. C.}",
year = "2001",
doi = "10.1053/jcpa.2001.0488",
language = "English",
volume = "125",
pages = "130--136",
journal = "Journal of Comparative Pathology",
issn = "0021-9975",
publisher = "W.B. Saunders Ltd",
number = "2-3",

}

TY - JOUR

T1 - Metallothionein expression in canine and feline mammary and melanotic tumours

AU - Dincer, Z.

AU - Jasani, B.

AU - Haywood, S.

AU - Mullins, J. E.

AU - Fuentealba, I. C.

PY - 2001

Y1 - 2001

N2 - Moderate to strong immunohistochemical metallothionein (MT) positivity (MT expression) is associated with a poor prognosis in some human tumours. The aim of this study was to determine MT expression in mammary tumours and cutaneous melanomas in dogs and cats. Canine (67) and feline (47) mammary tumours, and cutaneous melanomas (canine 40, feline 26) were immunolabelled with MT monoclonal antibody E9. The overall incidence of MT expression of these tumours was similar to that observed in various human neoplasms. However, a striking interspecies difference was detected. In dogs, MT expression occurred in 100% of benign and 57% of malignant mammary tumours. In cats, however, 30% of malignant mammary tumours expressed MT but benign mammary tumours and cases of fibroadenomatous hyperplasia did not. Moderate to strong MT immunoreactivity was detected in 30% of benign and 25% of malignant cutaneous melanomas in dogs, and in 6% of malignant melanomas in cats. The findings in feline mammary tumours resembled findings reported in human breast cancer, but the cause of tumour-associated MT expression is unknown. Studies are in progress to determine whether the MT state (apo [metal-free] or holo [metal-bound]) accounts for the paradoxical association of MT expression with individual types of tumours and the animal species in which they arise.

AB - Moderate to strong immunohistochemical metallothionein (MT) positivity (MT expression) is associated with a poor prognosis in some human tumours. The aim of this study was to determine MT expression in mammary tumours and cutaneous melanomas in dogs and cats. Canine (67) and feline (47) mammary tumours, and cutaneous melanomas (canine 40, feline 26) were immunolabelled with MT monoclonal antibody E9. The overall incidence of MT expression of these tumours was similar to that observed in various human neoplasms. However, a striking interspecies difference was detected. In dogs, MT expression occurred in 100% of benign and 57% of malignant mammary tumours. In cats, however, 30% of malignant mammary tumours expressed MT but benign mammary tumours and cases of fibroadenomatous hyperplasia did not. Moderate to strong MT immunoreactivity was detected in 30% of benign and 25% of malignant cutaneous melanomas in dogs, and in 6% of malignant melanomas in cats. The findings in feline mammary tumours resembled findings reported in human breast cancer, but the cause of tumour-associated MT expression is unknown. Studies are in progress to determine whether the MT state (apo [metal-free] or holo [metal-bound]) accounts for the paradoxical association of MT expression with individual types of tumours and the animal species in which they arise.

UR - http://www.scopus.com/inward/record.url?scp=0034751224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034751224&partnerID=8YFLogxK

U2 - 10.1053/jcpa.2001.0488

DO - 10.1053/jcpa.2001.0488

M3 - Article

VL - 125

SP - 130

EP - 136

JO - Journal of Comparative Pathology

JF - Journal of Comparative Pathology

SN - 0021-9975

IS - 2-3

ER -